



3rd

Two Coasts of the Aegean

ILD & PH


October 29-November 1, 2026

Grand Hyatt İzmir
İstinyePark Hotel

TURKISH GREEK
WORKSHOP
İZMİR



A Collaboration Between the Schools
of Medicine, Ege University and the
University of Crete



ΠΕΡΙΦΕΡΕΙΑ
ΚΡΗΤΗΣ
REGION OF CRETE

POSTGRADUATE COURSES & SCIENTIFIC PROGRAM



Two Coasts of the Aegean, Turkish-Greek ILD & PH Workshop 3, will take place from 29 October to 1 November 2026 in Grand Hyatt İzmir İstinyePark, Türkiye. Approximately 250 physicians and researchers are expected to attend.

ABSTRACT SUBMISSION

Final submission deadline: Wednesday, September 4, 2026

The abstracts should be a full-text of one page and must include the following sections:

- Title
- Author Names
- Affiliations
- Aim
- Introduction
- Case Discussion
- Conclusion
- Contact Information of the Presenter

The abstract prepared in accordance with these guidelines must be submitted as a Word document to ild-ph@invictuscongress.org by the submission deadline.

Conference Participation Sponsorship:

Conference Registration	: 30 October & 31 October & 1 November 2026 (only conference participation)	335 Euro + 20% VAT
Course Registration	: 29 October 2026 (only course participation)	150 Euro + 20% VAT
Conference & Course Registration Package	: 29 October & 30 October & 31 October & 1 November 2026	410 Euro + 20% VAT
Accommodation	: 750 Euro + 10% VAT	
External Participation	: 420 Euro + 20% VAT	
Transport	: Contact Invictus Tourism	

Accommodation: The stay is planned to be at the Grand Hyatt İzmir İstinyePark Hotel on a bed-and-breakfast concept for 3 nights, from Thursday, October 29, 2026 (check-in) to Sunday, November 1, 2026 (check-out). As there is limited availability at the Hyatt Regency hotel, alternative accommodation options will be provided based on requests.

External Participation will be charge from the participations without accommodation.

Stand Sponsorship One unit (3x2 m) : 1700 Euro + 20% VAT

Two Coasts of the Aegean, Turkish-Greek ILD & PH Workshop 3, The authorized agent is Invictus Tourism and payments must be made to the bank account details provided below.

Invictus Tourism Account Information

Bank	: Garanti Bankası
Branch Name and Account Name	: Beyoğlu Ticari / 1671
Hesap Adı	: İnvictus Turizm Kongre ve Org. Hizm. Ltd. Şti.
IBAN (TL)	: TR87 0006 2001 6710 0006 2966 73
IBAN (EUR)	: TR57 0006 2001 6710 0009 0977 00
Explanation	: ILD-PH2026




3rd *Two Coasts of the Aegean*
ILD&PH
29 October- 1 November 20
Hyatt Regency İzmir
İstinyePark Hotel
TURKISH GREEK
WORKSHOP
İZMİR



INVITED INTERNATIONAL FACULTY



**TONIA
ADAMIDI**



**JUZAR
ALI**



**KATERINA
ANTONIOU**



**NAZIA
CHAUDHURI**



**RESAT
CINAR**



**OLIVER
DISTLER**



**FRANTZESKA
FRANTZESKAKI**



**DIMITRIS
GEORGOPOULOS**



**ARDESCHIR
GHOFRANI**



**MARC
HUMBERT**



**THEODOROS
KARAMPITSAKOS**



**GABOR
KOVACS**



**EFFROSYNI
MANALI**



**GEORGE
MARGARITOPOULOS**



**IOANNA
MITROUSKA**



**MARIA
MOLINA-MOLINA**

**The faculty members are listed in alphabetical order by surname.*



3rd *Two Coasts of the Aegean*
ILD&PH
29 October- 1 November 20
Hyatt Regency İzmir
İstinyePark Hotel
TURKISH GREEK
WORKSHOP
İZMİR



INVITED INTERNATIONAL FACULTY



**IFIGENIA
NAKOU**



**HELMUT
PROSCH**



**CHRISTINA
RAMPIADOU**



**CLAUDIA
RAVAGLIA**



**LUCA
RICHELDI**



**PILAR
RIVERA-ORTEGA**



**DAVID
SCHWARTZ**



**KONSTANTINA
SYMVOULAKI**



**EMMANOUIL
SYMVOULAKIS**



**EKREM
TEMİZEL**



**IOANNIS
TOMOS**



**IRAKLIS
TSAGKARIS**



**NIKOLAOS
TZANAKIS**



**ARGYRIS
TZOUVELEKIS**



**THEODOROS
VASSILAKOPOULOS**



**WIM
WUYTS**

**The faculty members are listed in alphabetical order by surname.*



ILD POSTGRADUATE COURSE

29 October 2026 - PRE-CONGRESS DAY

HALL A - Practical ILD Masterclass

09:00-10:50	ILD Course Session I Practical diagnosis and early decision-making
09:00-09:10	Welcome and course objectives
09:10-09:35	How to approach a new ILD patient in 2026
09:35-10:00	HRCT pattern recognition in fibrotic ILD: A practical approach
10:00-10:25	Physiology of advanced lung disease: What PFTs and exercise reveal
10:25-10:50	IPF, PPF and non-IPF fibrosis: Practical distinctions
10:50-11:20	Coffee break
11:20-13:00	ILD Course Session II Phenotypes, tissue, management and referral
11:20-11:45	When to consider genetic testing at the diagnosis of fibrotic ILDs?
11:45-12:10	CTD-ILD for pulmonologists: Red flags and referral triggers
12:10-12:35	Cryobiopsy, pathology and MDD: Where tissue still matters
12:35-13:00	Advanced ILD and transplant referral: Timing, risk and the window of opportunity
13:00-14:00	Lunch
14:00-15:15	Speed MDD: Five images, five diagnoses, five decisions
14:00-14:15	Case 1
14:15-14:30	Case 2
14:30-14:45	Case 3
14:45-15:00	Case 4
15:00-15:15	Case 5
15:15-15:45	Coffee break
15:45-16:45	Young ILD Case Forum: "What would you do next?"
15:45-16:00	Case 1
16:00-16:15	Case 2
16:15-16:30	Case 3
16:30-16:45	Case 4



PH POSTGRADUATE COURSE

29 October 2026 - PRE-CONGRESS DAY

HALL B - PAH and PH Masterclass

09:00-10:50	PH Course Session I First evaluation, haemodynamics and risk
09:00-09:10	Welcome and course objectives
09:10-09:35	PH classification in 2026: Distinguishing group 1, group 2, group 3 and CTEPH at first evaluation
09:35-10:00	Advanced RHC workshop: Borderline haemodynamics, difficult tracings and clinical decisions
10:00-10:25	Echocardiography in PH: From suspicion to follow-up
10:25-10:50	Practical risk stratification in PAH: Applying low-risk goals in daily care
10:50-11:20	Coffee break
11:20-13:00	PH Course Session II Treatment, RV function and difficult haemodynamics
11:20-11:45	PAH treatment algorithms: A practical stepwise approach
11:45-12:10	RV function in PAH: What cardiologists add to the PH team
12:10-12:35	RHC fundamentals in PH: Numbers, waveforms and common interpretation traps
12:35-13:00	Interactive case synthesis: Applying risk, RV function and RHC data to PAH treatment decisions
13:00-14:00	Lunch
14:00-15:15	PH Case Board Three patients, three pathways
14:00-14:25	Case 1
14:25-14:50	Case 2
14:50-15:15	Case 3
15:15-15:45	Coffee break
15:45-16:45	Case-based discussion: BPA and pulmonary endarterectomy experiences



ILD AND GROUP 1 PAH AS DISTINCT DISEASES

30 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 1

08:30-09:00	Opening Ceremony The Aegean Bridge: From Collaboration to a Shared Scientific Network
09:00-10:20	SESSION I Fibrotic ILD in 2026: Phenotypes, Progression and Treatment Timing
09:00-09:20	Fibrotic ILD in 2026: From slowing decline to changing disease trajectory
09:20-09:40	Early fibrotic ILD and ILA: When does risk become disease?
09:40-10:00	Progressive pulmonary fibrosis: One syndrome or many diseases?
10:00-10:20	Clinical-radiological progression: What should trigger treatment change?
10:20-10:50	Coffee break
10:50-12:10	SESSION II Under-recognised and High-impact ILD Phenotypes
10:50-11:10	Hypersensitivity pneumonitis in 2026: From antigen identification to long-term management
11:10-11:30	IPF and lung cancer: How screening CT is changing the early detection of ILD and ILD-lung cancer overlap
11:30-11:50	Drug-induced ILD in the era of immune checkpoint inhibitors
11:50-12:10	Panel discussion: Is modern medicine creating a new ILD population?
12:10-13:00	Lunch Satellite Symposium I Genetics and Precision Medicine in Pulmonary Fibrosis
12:10-12:35	Journey in discovering and studying MUC5B in pulmonary fibrosis
12:35-13:00	Familial Pulmonary Fibrosis: When to Suspect, When to Test and How to Counsel Families



ILD AND GROUP 1 PAH AS DISTINCT DISEASES

30 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 1

13:00-14:20	SESSION III Group 1 PAH: Modern Phenotyping and Disease-modifying Treatment
13:00-13:25	Group 1 PAH in 2026: From risk stratification to disease modification
13:25-13:45	Haemodynamic and clinical phenotyping in PAH: Beyond classification
13:45-14:05	Next-generation PAH treatment: From risk-based escalation to precision therapy
14:05-14:20	Right ventricular-pulmonary arterial coupling as a treatment target in PAH
14:20-14:50	Coffee break & Group Photograph
14:50-15:50	PRO-CON DEBATE Antifibrotic Therapy in Fibrotic ILD: Treat Early or Wait for Progression?
14:50-15:05	Pro: Early treatment prevents irreversible fibrotic burden in IPF
15:05-15:20	Con: Treatment should be guided by documented progression and phenotype, not by early fibrosis alone
15:20-15:50	Crossfire and expert synthesis
15:50-16:20	Coffee break
16:20-17:50	PAH CLINICAL COURTROOM Upfront Intensive Therapy or Personalised Escalation?
16:20-16:40	Case 1: Young idiopathic PAH with high-risk features
16:40-17:00	Case 2: Older PAH patient with comorbidities: True PAH or mixed phenotype?
17:00-17:20	Case 3: Systemic sclerosis-associated PAH: Vascular disease, lung disease or both?
17:20-17:50	Courtroom verdict: What should change in treatment strategy?



PH-ILD, CTD-ILD/PAH, IMAGING AND TRIALS

31 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 2

08:30-09:00	Morning Keynote When fibrosis meets the pulmonary circulation: The PH-ILD challenge
09:00-10:20	SESSION IV PH-ILD and the Grey Zone: PAH, Group 3 PH or Both?
09:00-09:18	PH-ILD in 2026: Definitions, phenotypes and clinical consequences
09:18-09:36	Severe PH with mild ILD: PAH with lung involvement or PH-ILD?
09:36-09:54	The ILD clinician's view: When PH changes prognosis and treatment strategy
09:54-10:12	Turkish PH-ILD experience: Lessons from difficult clinical cases
10:12-10:20	Panel question: "When should we catheterise the ILD patient?"
10:20-10:50	Coffee break
10:50-12:10	SESSION V Imaging and AI at the Fibrosis-Vascular Interface
10:50-11:10	Quantitative CT in PPF and PH-ILD: Promise, limitations and clinical reality
11:10-11:30	AI-derived CT vascular, airway and textural metrics as trial endpoints in pulmonary fibrosis
11:30-11:50	From parenchyma to pulmonary vessels: CT clues to vascular remodelling in fibrotic ILD
11:50-12:10	Hot discussion: "AI says progression, clinician says stability – Who wins?"
12:10-13:10	Lunch Satellite Symposium II Targeted Therapies Across the Fibrosis-Vascular Spectrum



PH-ILD, CTD-ILD/PAH, IMAGING AND TRIALS

31 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 2

13:10-14:30	SESSION VI Autoimmune Disease at the Crossroads: CTD-ILD, CTD-PAH and CTD-PH-ILD
13:10-13:30	Systemic sclerosis-associated ILD: What has changed in treatment strategy?
13:30-13:50	Systemic sclerosis-associated PAH: A model disease for Group 1 PAH
13:50-14:10	CTD-ILD with PH: One patient, two pathways, one decision
14:10-14:30	Should every CTD-ILD patient be screened for PH?
14:30-15:30	GREAT DEBATE PH-ILD Treatment: Are We Treating the Lung, the Vessel or the Wrong Patient?
14:30-14:50	Position 1: The main target is the fibrotic lung
14:50-15:10	Position 2: The main target is the pulmonary vasculature in selected patients
15:10-15:30	Position 3: The main target is phenotyping before treating
15:30-16:00	Coffee break
16:00-17:15	SESSION VII Genetic and Molecular Frontiers in Progressive Pulmonary Fibrosis
16:00-16:25	The paradigm of Hermansky Pudlak syndrome in Greece, Cyprus and Türkiye
16:25-16:50	Multi-Omics Uncovers Shared Biomarkers and Immune Mechanisms of Progressive Pulmonary Fibrosis: Toward Precision Medicine Across the ILD Spectrum
16:50-17:15	Loss-of-Function Variants in LRRK2 Cause Interstitial Lung Disease with Storage Disease-like Features
17:15-17:30	Break



PH-ILD, CTD-ILD/PAH, IMAGING AND TRIALS

31 October 2026

MAIN SCIENTIFIC PROGRAMME DAY 2

17:30-18:45	TRIALISTS' ARENA Designing the Next Generation of ILD, PAH and PH-ILD Trials
17:30-17:45	Trial enrichment in fibrotic ILD: Selecting the right patient before progression
17:45-18:00	PAH trials beyond 6MWD: Risk, RV function and clinical worsening
18:00-18:15	PH-ILD trials: Which patient, which endpoint, which therapy?
18:15-18:30	Translational targets: From vascular remodelling to fibrosis modification
18:30-18:45	One impossible question: "If we designed the perfect ILD-PH trial today, what would the primary endpoint be?"

COLLABORATIVE CLINICAL RESEARCH


01 NOVEMBER 2026

HALF-DAY SCIENTIFIC PROGRAMME

09:30-10:30	Oral Presentation Session
10:30-10:45	Coffee Break
10:45-12:00	TURKISH-GREEK COLLABORATIVE RESEARCH FORUM Completed, Ongoing and Proposed Studies
10:45-11:00	What Have We Already Built Together? Lessons from Previous Turkish-Greek ILD Collaborations
11:00-11:15	Completed and Ongoing ILD Cohorts: What Can Be Analysed, Published or Expanded?
11:15-11:30	Toward an Aegean PH-ILD Registry: Haemodynamics, Imaging, Physiology and Outcomes
11:30-12:00	Investigator Publication Pipeline for 2027
12:00-12:30	Closing and Award Ceremony



A Collaboration Between the Schools
of Medicine, Ege University and the
University of Crete



3rd

Two Coasts of the Aegean

ILD & PH

October 29-November 1, 2026

Grand Hyatt İzmir
İstinyePark Hotel

TURKISH GREEK
WORKSHOP
İZMİR

Organisation Committee

Nesrin Moğulkoç Bishop

Professor of Respiratory Medicine with Expertise in
Interstitial Lung Disease and Pulmonary Hypertension
Ege University School of Medicine Department of
Respiratory Medicine Bornova, İzmir, Türkiye

Katerina Antoniou

Professor of Respiratory Medicine and
Head of Lab. of Cellular and Molecular
Pulmonology, University of Crete,
Greece



Organization Secretariat

19 Mayıs Mah. Halaskargazi Cad. T. Cemal Sk.
Cumhuriyet Apt. No:7 D:1, 34360 Şişli / İstanbul-Türkiye
Phone: +90 212 230 78 68 - Fax: +90 212 234 78 68

E-mail: ild-ph@invictuscongress.org - www.invictuscongress.org